Monash IVF Group Ltd (ASX: MVF) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Monash IVF Group Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$457.82 million
P/E Ratio
27.55
Dividend Yield
3.71%
Shares Outstanding
389.63 million
Earnings per share
0.043
Dividend per share
0.04
Year To Date Return
26.39%
Earnings Yield
3.63%
Franking
100%
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Monash IVF Group Ltd (ASX: MVF)
Latest News
Value Investing
Don’t get duped: Why cheap ASX shares can still rip you off
Healthcare Shares
50% upside: The small-cap ASX share that has everything going for it
Broker Notes
Wake up! Buy 5 ASX shares that are reporting season gems: Morgans
Small Cap Shares
3 ASX shares I think are primed to break out in 2023
Broker Notes
Leading brokers name 3 ASX shares to buy today
Broker Notes
Leading brokers name 3 ASX shares to buy today
Broker Notes
Leading brokers name 3 ASX shares to buy today
Dividend Investing
5 ASX All Ords shares trading ex-dividend on Thursday
Broker Notes
6 ASX shares Morgans would buy right now
Dividend Investing
Buy these good value ASX dividend shares: brokers
Share Gainers
Why BlueScope, Firefinch, Monash IVF, and South32 shares are pushing higher
Share Fallers
Why Imugene, Integrated Research, Monash IVF, and Step One shares are sinking
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 08 Mar 2023 | $0.0220 | 100.00% | Interim | 06 Apr 2023 |
| 08 Sep 2022 | $0.0220 | 100.00% | Final | 07 Oct 2022 |
| 07 Mar 2022 | $0.0220 | 100.00% | Interim | 04 Apr 2022 |
| 09 Sep 2021 | $0.0210 | 100.00% | Final | 08 Oct 2021 |
| 09 Mar 2021 | $0.0210 | 100.00% | Interim | 07 Apr 2021 |
| 05 Mar 2020 | $0.0210 | 100.00% | Interim | 02 Oct 2020 |
| 05 Sep 2019 | $0.0300 | 100.00% | Final | 11 Oct 2019 |
| 06 Sep 2018 | $0.0260 | 100.00% | Final | 12 Oct 2018 |
| 08 Mar 2018 | $0.0340 | 100.00% | Interim | 06 Apr 2018 |
| 06 Sep 2017 | $0.0000 | 100.00% | Final | 13 Oct 2017 |
| 02 Mar 2017 | $0.0430 | 100.00% | Interim | 07 Apr 2017 |
| 06 Sep 2016 | $0.0450 | 100.00% | Final | 14 Oct 2016 |
| 08 Mar 2016 | $0.0400 | 100.00% | Interim | 08 Apr 2016 |
MVF ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Monash IVF Group Ltd
Monash IVF Group Ltd is a specialist assisted reproductive services provider. The company offers specialist diagnostic obstetric and gynaecological ultrasound and fertility treatments. The company's operating segment includes Australia andInternational. It generates maximum revenue from the Australian segment. Australian segment is a provider of Assisted Reproductive Services, Ultrasound, and other related services. The International segment is a provider of Assisted Reproductive Services in Malaysia.
MVF Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 09 Aug 2023 | $1.18 | $-0.01 | -0.84% | 354,083 | $1.18 | $1.19 | $1.17 |
| 08 Aug 2023 | $1.19 | $0.01 | 0.85% | 107,090 | $1.20 | $1.20 | $1.17 |
| 07 Aug 2023 | $1.18 | $0.00 | 0.00% | 139,311 | $1.21 | $1.21 | $1.18 |
| 04 Aug 2023 | $1.18 | $-0.01 | -0.84% | 102,491 | $1.20 | $1.20 | $1.18 |
| 03 Aug 2023 | $1.19 | $-0.02 | -1.65% | 197,090 | $1.21 | $1.21 | $1.18 |
| 02 Aug 2023 | $1.21 | $-0.01 | -0.82% | 2,908,768 | $1.22 | $1.22 | $1.21 |
| 01 Aug 2023 | $1.22 | $0.01 | 0.83% | 171,034 | $1.21 | $1.22 | $1.21 |
| 31 Jul 2023 | $1.21 | $-0.01 | -0.82% | 308,994 | $1.22 | $1.22 | $1.20 |
| 28 Jul 2023 | $1.22 | $0.00 | 0.00% | 524,436 | $1.22 | $1.22 | $1.20 |
| 27 Jul 2023 | $1.22 | $0.01 | 0.83% | 427,591 | $1.20 | $1.22 | $1.19 |
| 26 Jul 2023 | $1.21 | $0.01 | 0.84% | 1,342,958 | $1.18 | $1.21 | $1.18 |
| 25 Jul 2023 | $1.20 | $0.00 | 0.00% | 398,837 | $1.20 | $1.21 | $1.20 |
| 24 Jul 2023 | $1.20 | $0.02 | 1.70% | 1,844,256 | $1.19 | $1.21 | $1.18 |
| 21 Jul 2023 | $1.18 | $0.00 | 0.00% | 200,502 | $1.18 | $1.19 | $1.18 |
| 20 Jul 2023 | $1.18 | $-0.02 | -1.67% | 140,618 | $1.18 | $1.20 | $1.17 |
| 19 Jul 2023 | $1.20 | $0.03 | 2.58% | 290,416 | $1.18 | $1.20 | $1.17 |
| 18 Jul 2023 | $1.17 | $-0.03 | -2.50% | 598,133 | $1.20 | $1.20 | $1.16 |
| 17 Jul 2023 | $1.20 | $0.00 | 0.00% | 4,163,233 | $1.20 | $1.20 | $1.18 |
| 14 Jul 2023 | $1.20 | $0.03 | 2.58% | 755,097 | $1.17 | $1.20 | $1.16 |
| 13 Jul 2023 | $1.17 | $0.02 | 1.75% | 777,973 | $1.14 | $1.17 | $1.14 |
| 12 Jul 2023 | $1.15 | $0.00 | 0.00% | 269,318 | $1.15 | $1.17 | $1.14 |
| 11 Jul 2023 | $1.15 | $0.01 | 0.88% | 1,496,320 | $1.15 | $1.15 | $1.14 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 21 Nov 2022 | Michael Knaap | Issued | 540 | $540,170 |
Issue of securities. 15,07,965 Performance Rights, As per announcement on 21-11-2022
|
| 21 Nov 2022 | Michael Knaap | Issued | 532 | $532,599 |
Issue of securities. 15,00,394 RIGHTS, AS PER ANNOUNCEMENT ON 24-11-2022
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Zita Peach | Non-Executive Director | Oct 2016 |
Ms Peach has more than 30 years of commercial experience in the pharmaceutical, biotechnology, medical devices and health services industries, and has worked for major industry players such as Fresenius Kabi (Executive Vice President, Asia Pacific), CSL Limited (Vice President, Business Development) and Merck Sharp & Dohme (Commercial Director), the Australian subsidiary of Merck Inc.
|
| Mr Josef Jerzy Czyzewski | Non-Executive Director | Jun 2014 |
Mr Czyzewski has over 30 years of experience in senior finance positions and experience in the health industry. Josef has held the positions of CFO at Healthscope Limited, and more recently CFO/ General Manager Strategy and Development at Spotless Group Limited following its takeover by private equity interests in 2012. Prior to that time, Josef had held various senior finance positions with BHP Billiton including VP Finance and Corporate Treasurer.
|
| Mr Richard Hugh Davis | Non-Executive ChairmanNon-Executive Director | Jun 2014 |
Mr Davis worked for InvoCare for 20 years until 2008. For the majority of that time he held the position of CEO and managed the growth of that business through a number of ownership changes and over 20 acquisitions, including offshore in Singapore. Prior to InvoCare Limited, Richard worked as an accounting partner of Bird Cameron.
|
| Mr Neil John Broekhuizen | Non-Executive Director | Jun 2014 |
Mr Broekhuizen has over 30 years experience in the finance industry, including 28 years in private equity with Investcorp and Bridgepoint in Europe and Ironbridge in Australia. He has sat on the Ironbridge Investment Committee since inception. He is the Independent Non-executive Chairman of Bravura Solutions.
|
| Mr Michael Damian Knaap | Chief Executive OfficerManaging Director | Sep 2015 |
Mr Knaap has nearly 20 years experience in executive positions with a strong operational, strategic and leadership background. Prior to joining MVF Group, Michael was with Patties Foods Limited where he held a number of executive positions over six years, including the role of Chief Financial Officer and Company Secretary.
|
| Dr Richard Charles Henshaw | Executive Director | Apr 2014 |
Dr Henshaw has practiced in the field of reproductive medicine since 1995. Richard works as a Fertility Specialist for the Group. Richard has served on many national bodies, including RANZCOG Council, the IVF Medical Directors Group of Australia and New Zealand, and the Reproductive Technology Accreditation Committee.
|
| Ms Catherine Jane West | Non-Executive Director | Sep 2020 |
Ms Catherine has over 25 years of legal, business affairs and strategy experience in customer focused businesses in the media, entertainment, telecommunications and medical sectors in Australia, the UK and Europe. She is a director of the Sydney Breast Cancer Foundation Limited, a director of the National Institute of Dramatic Art (NIDA) and the NIDA Foundation and is Chair of the Board of Governors of Wenona School.
|
| Mr Malik Jainudeen | Chief Financial OfficerCompany Secretary | Apr 2019 |
-
|
| Jan Lagerwij | Asia Managing Director |
-
|
|
| May Q, Loke | Centre Manager KLFGC |
-
|
|
| Malik Jainudeen | Chief Financial OfficerCompany Secretary |
-
|
|
| Tedd Fuell | Chief Governance & Risk Officer |
-
|
|
| Thierry Panthier | Chief Information Officer |
-
|
|
| Fiona Allen | Chief Marketing Officer |
-
|
|
| Hamish Hamilton | Chief Operating Officer |
-
|
|
| Peggy North | Chief People & Culture Office |
-
|
|
| Deirdre Zander-Fox | Chief Scientific Officer |
-
|
|
| Denise Donati | Fertility Solutions Queensland Manager |
-
|
|
| Anthony Gurney | General Manager of SUFW |
-
|
|
| Sloane Karlson | General Manager Projects |
-
|
|
| Prof Luk Rombauts | Group Medical Director |
-
|
|
| Sarah Bollom | Regional donor & Surrogacy Manager |
-
|
|
| Ben Howat | Regional Manager QLD |
-
|
|
| Rebecca Redden | Regional Manager SA & NT |
-
|
|
| Nicolette Curtis | Regional Manager VIC |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Citicorp Nominees Pty Limited | 69,209,123 | 17.76% |
| J P Morgan Nominees Australia Pty Limited | 58,147,730 | 14.92% |
| Hsbc Custody Nominees (Australia) Limited | 49,121,083 | 12.61% |
| National Nominees Limited | 46,751,322 | 12.00% |
| Argo Investments Limited | 19,982,646 | 5.13% |
| Washington H Soul Pattison And Company Limited | 14,083,474 | 3.61% |
| BNP Paribas Noms Pty Ltd <Drp> | 8,213,289 | 2.11% |
| Ubs Nominees Pty Ltd | 6,028,740 | 1.55% |
| Buttonwood Nominees Pty Ltd | 6,021,948 | 1.55% |
| BNP Paribas Nominees Pty Ltd <Agency Lending DRP A/C> | 5,749,429 | 1.48% |
| Hsbc Custody Nominees (Australia) Limited A/C 2 | 4,144,480 | 1.06% |
| Neweconomy Com Au Nominees Pty Limited <900 Account> | 3,916,085 | 1.01% |
| Pacific Custodians Pty Limted <Ordinary Unit Tst A/C> | 2,474,369 | 0.64% |
| Ippoliti Pty Ltd <Ippoliti Family Trust A/C> | 2,011,336 | 0.52% |
| Brispot Nominees Pty Ltd <House Head Nominee A/C> | 1,718,621 | 0.44% |
| BNP Paribas Nominees Pty Ltd <Ib Au Noms Retail Client Drp> | 1,682,086 | 0.43% |
| Mr Prashant Nadkarni | 1,461,484 | 0.38% |
| Vollenhoven Investment Pty Ltd <Vollenhoven Family A/C> | 1,447,787 | 0.37% |
| Mclachlan Future Fund Pty Ltd <R & E Mclachlan S/F A/C> | 1,385,944 | 0.36% |
| Ong Administration Pty Ltd <The Ong Family Trust A/C> | 1,201,906 | 0.31% |